Guilherme Godoy, MD, MPH

Guilherme Godoy, MD, MPH

Baylor College of Medicine

Houston, Texas

Dr. Godoy is an Assistant Professor of Urology and Urology Oncology at Baylor College of Medicine, Houston, Texas. He received his MD from Fundacao Universitaria do ABC in Sao Paulo, Brazil, and has received numerous fellowships at several institutions, including Memorial Sloan Kettering Cancer Center in New York City, Irmandade da Santa Casa de Misericordia de Sao Paulo Medical School in Sao Paulo, Brazil, Vancouver General Hospital in Vancouver, British Columbia, New York University School of Medicine in New York City, and Baylor College of Medicine. Dr. Godoy is skilled at managing patients with bladder cancer, kidney cancer, prostate cancer, and testis cancer. He also specializes in bladder issues, erectile dysfunction, kidney stones, and prostatitis. Dr. Godoy is a respected writer, researcher, and presenter as well, and has published numerous articles and papers. He has won a Best Published Clinical Research Paper Award from European Urology and has been recognized on several occasions as a Best Poster of the Section at American Urological Association Annual Meetings and European Association of Urology Annual Congresses. Dr. Godoy is also heavily involved in the medical community, both nationally and internationally. He is a member or candidate member of nine medical societies, including the Pan American Society of Anatomy, the Brazilian Society of Anatomy, the American Association of Cancer Research, and the Southwest Oncology Group.

Disclosures:

Articles by Guilherme Godoy, MD, MPH

Urologic Debate Part 1: MRI vs. Molecular Markers – Which One Should I Use? MRI Perspective

In the first part of this urologic debate, Guilherme Godoy, MD, MPH, Assistant Professor of Urology and Urology Oncology at Baylor College of Medicine in Houston, Texas, argues for multiparametric MRI (mpMRI) as the better diagnostic tool for finding prostate cancer as compared to molecular markers. He observes that while there are many different commercial markers available to aid decision-making before diagnosis, at initial diagnosis, and after treatment, mpMRI can help in all three of these prostate cancer management spaces. Dr. Godoy also argues that while molecular tests may inform risk, a biopsy preceded by MRI will still be necessary, and that biopsy can be improved and optimized by mpMRI. He then discusses different techniques and equipment that can be used with mpMRI, how to interpret and report the results from mpMRI, and the trial evidence for mpMRI’s effectiveness. Dr. Godoy concludes that mpMRI functions as “the ideal biomarker,” as it increases accuracy and decreases the number of biopsies and helps to optimize care after cancer diagnosis.

Read More

Prostate Cancer Early Diagnosis Screening

Guilherme Godoy, MD, MPH, details the controversies surrounding the evolving United States Preventive Services Task Force (USPSTF) recommendations on PSA screening. He then emphasizes the need for individualizing risk assessment in clinical decisions-making for prostate cancer.

Read More

Management of Upper Tract Urothelial Cancer

Guilherme Godoy, MD, MPH, provides a brief overview of the pathogenesis and epidemiology of upper tract urothelial carcinoma (UTUC). He then reviews genomic classification, diagnosing and staging, current oncological principles of surgical therapy, and new risk-adapted treatment options for the disease.

Read More

Join the GRU Community

- Why Join? -